Key Highlights

  • Revenue from continuing operations was USD 65.414 million, against USD 56.425 million in the third quarter of 2025.
  • Loss per share from continuing operations was USD 0.05, against an estimate of a USD 0.07 loss.
  • Global Products Operating Income was USD 6.0 million, and the Innovative Biotech loss from operations was USD 26.841 million.
  • Cash and restricted cash were about USD 403.2 million, and the 2044 Royalty notes Facility stands at USD 375.0 million.

OPKO Health (NASDAQ:OPK) reported third quarter results that present diagnostics separately after its board approved a plan on September 30 to sell substantially all remaining BioReference operations to Labcorp. An Asset Purchase Agreement followed on October 14. Continuing operations produced Revenue of USD 65.414 million and a loss of USD 0.05 per share, which compares with an estimate of a USD 0.07 loss.

Revenue From Continuing Operations

Total revenue was USD 65.414 million, against USD 56.425 million a year earlier. Management attributed the change to higher royalty revenue from Eli Lilly, increased Rayaldee sales and growth in international operations. For the nine months, revenue was USD 206.456 million, against USD 159.239 million.

Global Products revenue was USD 48.449 million, against USD 39.44 million. Revenue from products was USD 41.811 million, against USD 37.676 million, and Rayaldee sales were USD 8.6 million, against USD 7.5 million, which the company linked to gross-to-net adjustments after changes to Medicare coverage. Licensing, collaboration and other revenue in that segment was USD 6.638 million, including USD 5.8 million of royalty revenue from Eli Lilly. Innovative Biotech licensing, collaboration and other revenue was USD 17.0 million in both periods, with lower BARDA contract revenue offset by Regeneron collaboration revenue.

Operating Loss, Net Loss and Per-Share Results

The operating loss was USD 31.409 million, against USD 33.554 million a year earlier. Cost of revenue was USD 23.351 million, selling, general and administrative expense was USD 24.837 million, and Research and Development expense was USD 32.177 million. Within Global Products, research and development expense was USD 1.621 million, against USD 3.307 million, which included a USD 1.373 million Irish tax credit.

Net loss from continuing operations was USD 35.556 million, against USD 32.92 million, and included a USD 5.0 million loss from investments in investees. Net loss was USD 53.534 million, against Net Income of USD 21.631 million a year earlier, and the company reported a loss per share of USD 0.07 including discontinued operations. Innovative Biotech research and development expense was USD 30.4 million, against USD 26.3 million, which the company tied to ModeX programs advancing through preclinical and clinical work.

Cash, Royalty Notes and Buybacks

Cash, cash equivalents and restricted cash were about USD 403.2 million at September 30. Over nine months, Operating Activities used USD 99.1 million, investing activities provided USD 25.0 million and financing activities provided USD 96.3 million. Financing included net proceeds of about USD 123.1 million from an added USD 125.0 million of 2044 royalty financing notes, raising the facility to USD 375.0 million, partly offset by USD 28.4 million of share repurchases.

The company repurchased 20,835,105 shares at an average USD 1.37 during the nine months. It also received about USD 19.8 million from released Escrow funds in the third quarter, and management noted there is no additional earnout consideration to be received from the 2025 oncology diagnostics sale. Management stated that cash on hand supports operations and Debt service beyond the next 12 months.

Key Figures Side by Side

Revenue of USD 65.414 million sits alongside an operating loss of USD 31.409 million, a loss per share from continuing operations of USD 0.05 and cash of about USD 403.2 million.

Management named the Labcorp sale, under the October 14 agreement, as the pending event, with diagnostics already shown as discontinued operations. It also pointed to the August 13 expansion of the royalty notes, which now include certain Eli Lilly mazdutide royalty receivables in the Collateral framework, and the April 30 Nicoya amendment, under which EirGen received a 15% Equity interest in Nicoya's parent.